Meeting
2021 Genitourinary Cancers Symposium
A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma.
Authors
Maria Isabel Carlo
Memorial Sloan Kettering Cancer Center, New York, NY
Maria Isabel Carlo , Kyrollis Attalla , Sujata Patil , Samuel J. Murray , Ying-Bei Chen , Ritesh Kotecha , Jeremy C. Durack , Robert J. Motzer , A. Ari Hakimi , Martin H Voss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02595918
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 323)
DOI
10.1200/JCO.2021.39.6_suppl.323
Abstract #
323
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.
First Author: Naomi B. Haas
Poster
2021 ASCO Annual Meeting
Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
First Author: Axel Bex
Poster
2023 ASCO Genitourinary Cancers Symposium
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
First Author: Nirmish Singla
Poster
2022 ASCO Annual Meeting
IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
First Author: Arndt Vogel